PMID- 24772319
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 2
IP  - 3
DP  - 2014 May
TI  - Safety and continuity of second- and third-line therapy with paclitaxel or 
      irinotecan for advanced and recurrent gastric cancer.
PG  - 466-472
AB  - In the treatment of advanced or recurrent gastric cancer, the prolongation of 
      survival depends on the use of second-line therapy, with paclitaxel (PTX) or 
      irinotecan (CPT-11) as the key agents. The present study aimed to retrospectively 
      investigate the safety and continuity of weekly PTX and CPT-11 monotherapy as 
      second- or third-line treatment for advanced or recurrent gastric cancer. A total 
      of 62 patients who had received PTX or CPT-11 for gastric cancer at the Ogaki 
      Municipal Hospital (Ogaki, Japan) were retrospectively reviewed. Of the 47 
      patients who received PTX as second-line therapy, 13 (27.7%) received third-line 
      therapy with CPT-11. Second-line PTX and third-line CPT-11 were discontinued due 
      to progressive disease (PD) in 27 and 7 cases, respectively, and deterioration in 
      the performance status (PS) in 20 and 4 cases, respectively. Only 1 case of 
      discontinuation due to adverse events (AEs) was reported for third-line CPT-11. 
      Furthermore, of the 15 patients who received CPT-11 as second-line treatment, 11 
      (73.3%) then received PTX as third-line treatment. Second-line CPT-11 and 
      third-line PTX were discontinued due to PD in 9 and 6 cases, respectively, and 
      deterioration in the PS in 4 and 5 cases, respectively, whereas there was only 1 
      case of discontinuation due to AEs for second-line CPT-11. Severe AEs for PTX and 
      CPT-11 were infrequent; however, the frequency of diarrhea was high when PTX was 
      administered as third-line therapy (63.6%), whereas the frequency of malaise was 
      high when CPT-11 was administered as second- (73.3%) and third-line (76.9%) 
      therapy. In conclusion, severe AEs due to PTX and CPT-11 as second- and 
      third-line treatment for advanced or recurrent gastric cancer are infrequent and 
      patients are generally able to continue treatment. However, the possibility of 
      diarrhea with third-line PTX and malaise with second- and third-line CPT-11 
      treatment should be considered when planning chemotherapy.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan ;
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan ;
FAU - Kanematsu, Tetsufumi
AU  - Kanematsu T
AD  - Department of Pharmacy, Gifu Social Insurance Hospital, Kani, Gifu 509-0206, 
      Japan ;
FAU - Iwai, Mina
AU  - Iwai M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan ;
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan ;
FAU - Mori, Hiromi
AU  - Mori H
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan ;
FAU - Sugiyama, Tadashi
AU  - Sugiyama T
AD  - Laboratories of Pharmacy Practice and Social Science, Gifu Pharmaceutical 
      University, Gifu, Gifu 501-1196, Japan.
FAU - Teramachi, Hitomi
AU  - Teramachi H
AD  - Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu 501-1196, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140214
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC3999116
OTO - NOTNLM
OT  - continuity
OT  - gastric cancer
OT  - irinotecan
OT  - paclitaxel
OT  - safety
EDAT- 2014/04/29 06:00
MHDA- 2014/04/29 06:01
PMCR- 2014/02/14
CRDT- 2014/04/29 06:00
PHST- 2013/09/09 00:00 [received]
PHST- 2014/02/10 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/04/29 06:01 [medline]
PHST- 2014/02/14 00:00 [pmc-release]
AID - mco-02-03-0466 [pii]
AID - 10.3892/mco.2014.260 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2014 May;2(3):466-472. doi: 10.3892/mco.2014.260. Epub 2014 Feb 
      14.